NIH, ConverGene deal

ConverGene said it gained exclusive, worldwide rights from NIH's National Center for Advancing Translational Sciences (NCATS) to a portfolio of preclinical compounds targeting BET bromodomain proteins to treat or prevent mammalian diseases. ConverGene originally conceived of the compounds' core structures in-house, the company said. ConverGene and NCATS co-developed the portfolio under a cooperative research and development agreement (CRADA)...